Eli Lilly is slated to report third-quarter earnings and revenue on Thursday, which will likely be fueled by its blockbuster obesity drug Zepbound and diabetes counterpart Mounjaro. Here's what Wall Street is expecting, based on a survey of analysts by LSEG: But investors will also be laser-focused on the launch of the company's obesity pill, Foundayo, which entered the market in April. Analysts forecast around $229 million in sales for the pill, StreetAccount estimates showed. Lilly's massive diabetes and obesity windfall – and dominance over chief rival Novo – show no signs of slowing down, even as the company grapples with lower net prices in the U.S.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.